Interaction between Colesevelam and Mycophenolic acid
Major Absorption

ID DDInter432 and DDInter1252
Interaction Coadministration with bile acid sequestrants or activated charcoal may decrease the bioavailability of mycophenolic acid.
Management Given the risk of organ rejection associated with inadequate immunosuppressant blood levels, mycophenolic acid products should not be administered with cholestyramine or other agents that may interfere with enterohepatic recirculation or bind bile acids (e.g., activated charcoal).
References
Alternative for Colesevelam C10A
Pitavastatin
Rosuvastatin
Dextrothyroxine
Lovastatin
Bempedoic acid
Fenofibrate
Fenofibric acid
Cerivastatin
Clofibrate
Gemfibrozil
Fluvastatin
More
Alternative for Mycophenolic acid L04A
Muromonab
Lenalidomide
Tofacitinib
Alemtuzumab
Certolizumab pegol
Siponimod
Pomalidomide
Vedolizumab
Ocrelizumab
Brodalumab
Ozanimod
More

Potential Metabolism Interactions

Substrate-Substrate Interaction：If more than one drug is metabolized by the same CYP, it is possible that its metabolism is inhibited because of the competition between the drugs. That means, it can be useful to lower the dosage of the drugs in the drug-cocktail because they remain longer in the organism than in monotherapy.
Inhibitor-Inhibitor Interaction：Combining two or more inhibitors of one CYP, should be compensated by lowering the dosage of these drugs because the metabolism is reduced and the drugs remain longer in the organism than in monotherapy. Not adapting the dosage bears the risk of even more side effects.
Inhibitor-Substrate Interaction：Combining drugs that have inhibitory effect and are substrates of one particular CYP, should be compensated by lowering the dosage. They rest longer in the organism than in monotherapy. Not adapting the dosage bears the risk of even more side effects.